These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
26. The metabolism of mesalamine and its possible use in colonic diverticulitis as an anti-inflammatory agent. Cohen HD, Das KM. J Clin Gastroenterol; 2006 Aug; 40 Suppl 3():S150-4. PubMed ID: 16885699 [Abstract] [Full Text] [Related]
29. [Severe tubulo-interstitial nephritis secondary to 5-ASA]. Bosque López MJ, Garrido Durán C, Ginard Vicens D, Munar Vila MA, Vanrell Garau M, Mariño Méndez Z, Gayà Cantallops J. Gastroenterol Hepatol; 2009 Jan; 32(1):29-31. PubMed ID: 19174096 [Abstract] [Full Text] [Related]
30. Acute interstitial nephritis due to mesalazine. Tadic M, Grgurevic I, Scukanec-Spoljar M, Bozic B, Marusic S, Horvatic I, Galesic K. Nephrology (Carlton); 2005 Apr; 10(2):103-5. PubMed ID: 15877665 [Abstract] [Full Text] [Related]
31. Mesalamine-associated thrombocytopenia. Farrell RJ, Peppercorn MA, Fine SN, Michetti P. Am J Gastroenterol; 1999 Aug; 94(8):2304-6. PubMed ID: 10445572 [Abstract] [Full Text] [Related]
32. Treatment of distal ulcerative colitis: now the patients have the choice. Schölmerich J. Ital J Gastroenterol Hepatol; 1999 Nov; 31(8):685-7. PubMed ID: 10730560 [No Abstract] [Full Text] [Related]
33. Chronic tubulointerstitial nephritis induced by 5-aminosalicylate in an ulcerative colitis patient: a rare but serious adverse event. Magalhães-Costa P, Matos L, Chagas C. BMJ Case Rep; 2015 May 02; 2015():. PubMed ID: 25935912 [Abstract] [Full Text] [Related]
34. Effect of once- or twice-daily MMX mesalamine (SPD476) for the induction of remission of mild to moderately active ulcerative colitis. Lichtenstein GR, Kamm MA, Boddu P, Gubergrits N, Lyne A, Butler T, Lees K, Joseph RE, Sandborn WJ. Clin Gastroenterol Hepatol; 2007 Jan 02; 5(1):95-102. PubMed ID: 17234558 [Abstract] [Full Text] [Related]
35. Mesalazine and photosensitivity. Horiuchi Y, Shimakura S. Am J Gastroenterol; 1999 Nov 02; 94(11):3386-7. PubMed ID: 10566765 [No Abstract] [Full Text] [Related]
36. Delayed-release oral mesalamine 4.8 g/day (800-mg tablet) is effective for patients with moderately active ulcerative colitis. Sandborn WJ, Regula J, Feagan BG, Belousova E, Jojic N, Lukas M, Yacyshyn B, Krzeski P, Yeh CH, Messer CA, Hanauer SB. Gastroenterology; 2009 Dec 02; 137(6):1934-43.e1-3. PubMed ID: 19766640 [Abstract] [Full Text] [Related]
37. Practicality of 5-aminosalicylic suppositories for long-term treatment of inactive distal ulcerative colitis. Casellas F, Vaquero E, Armengol JR, Malagelada JR. Hepatogastroenterology; 1999 Dec 02; 46(28):2343-6. PubMed ID: 10521994 [Abstract] [Full Text] [Related]
38. [Ulcerative colitis. When is standard therapy enough?]. Stange EF. MMW Fortschr Med; 2000 Oct 12; 142(41):39-40. PubMed ID: 11085075 [No Abstract] [Full Text] [Related]
39. Pulmonary complications in patients with inflammatory bowel disease. Kuzela L, Vavrecka A, Prikazska M, Drugda B, Hronec J, Senkova A, Drugdova M, Oltman M, Novotna T, Brezina M, Kratky A, Kristufek P. Hepatogastroenterology; 1999 Oct 12; 46(27):1714-9. PubMed ID: 10430329 [Abstract] [Full Text] [Related]
40. Acute pancreatitis after long-term 5-aminosalicylic acid therapy. Fernández J, Sala M, Panés J, Feu F, Navarro S, Terés J. Am J Gastroenterol; 1997 Dec 12; 92(12):2302-3. PubMed ID: 9399776 [Abstract] [Full Text] [Related] Page: [Previous] [Next] [New Search]